Project Grant HT94252510622
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$480K
Federal Agency
Defense Health Agency
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
This Project Grant award from the Defense Health Agency provides $1,423,676 to Duke University from September 1, 2023 through August 31, 2026. The funding supports research targeting NUAK2 in neuroendocrine prostate cancer under the Military Medical Research and Development program (CFDA 12.420). The Military Medical Research and Development program aims to transform health care for service members and the public through innovative biomedical research. This award will further those goals by...
The federal Project Grant award of $481,158.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) enables Duke University to conduct research aimed at "Blocking Glutamine Utilization in Advanced and Therapy-Resistant Prostate Cancer." The award supports a two-year project from June 1, 2024 to May 31, 2026 to expand the frontiers of scientific knowledge and apply it to address a critical medical challenge facing military service...
The U.S. Defense Health Agency awarded a $1,449,000 Project Grant to Duke University to conduct research aimed at "Identifying Essential Molecular Mechanisms for Advanced Prostate Cancer Growth by a New Chemical Compound." This grant is funded under the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The...
The Department of Defense's Defense Health Agency awarded a $241,500 Project Grant to Duke University under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on September 1, 2025, supports research to understand the molecular communication between different types of prostate cancer cells. This fundamental research, to be conducted at Duke University in Durham, North Carolina, aims to transform healthcare for military service members, veterans, and the...
The Defense Health Agency awarded Duke University a $1,167,250 Project Grant (CFDA 12.420 - Military Medical Research and Development) with a performance period from June 1, 2024 to May 31, 2027. The grant funding supports Duke's research on the role of the NLRP3-NLRC5 signaling pathway in melanoma immune evasion and dormancy. The research aims to advance the understanding of mechanisms underlying melanoma progression, with the potential to inform new therapeutic approaches. As a prominent...
This $240,897 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, will support integrative transcriptomic and epigenomic profiling of subependymal giant cell astrocytoma at single-cell resolution. The award was made to Duke University's Office of Research Administration on August 1, 2025, with a period of performance through July 31, 2027. The Military Medical Research and Development program funds advanced biomedical...
This federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is funding research at the University of Kentucky Research Foundation focused on "Targeting MNK/GRP78 Pathway to Disrupt Proteostasis Rewiring in Castration-Resistant Prostate Cancer". The $1,602,137 award, spanning from April 2025 to April 2028, aims to investigate innovative medical solutions for military personnel and the broader...
The Department of Defense's Defense Health Agency awarded Duke University a $1,344,946 Project Grant on September 1, 2023 through the Military Medical Research and Development program (CFDA 12.420). This grant supports a 3-year research project titled "Understanding Heterogeneity and Improving the Precision of Prostate Cancer Clinical Outcomes in the Modern Era." The research aims to advance understanding and treatment of prostate cancer, with a focus on improving clinical outcomes for...
The federal Project Grant award of $2,136,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is focused on "REVERSIBILITY AND THERAPEUTIC TARGETING OF TREATMENT- EMERGENT NEUROENDOCRINE PROSTATE CANCER" and will be performed by the Dana-Farber Cancer Institute, Inc. (Dfci) located in Boston, MA. The grant supports advanced biomedical research aimed at transforming healthcare for military service members,...
The federal Project Grant award of $161,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Duke University to investigate breast cancer brain metastases. The research aims to integrate immunogenomic and phenotypic vulnerabilities to improve outcomes for this challenging condition. The award period runs from April 1, 2025 to March 31, 2026. This grant is part of the Defense Health Agency's strategic...